Neurocrine Biosciences shares are trading lower after the company reported Q2 financial results, and may be falling amid possible sympathy with Novo Nordisk after its ZEUS phase 3 trial did not translate into a MACE risk reduction. The stock previously collaborated with Transthera for NLRP3 inhibitors.